DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceuticals, today announced that Cornelia Reininger, M.D., Ph.D., has been named Chief Medical Officer of Navidea, effective November 1, 2012. The appointment coincides with the growing emphasis at Navidea on a broader pipeline, later-stage product candidate development, and commercial products.
